isoxazoles has been researched along with Cholangiocellular Carcinoma in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, PM; Chao, Y; Chen, MH; Chen, TW; Chen, YY; Cheng, CT; Chiang, KC; Huang, CY; Huang, SC; Jan, YY; Li, CP; Liu, CY; Wang, HM; Weng, JJ; Yeh, CN; Yeh, TS | 1 |
| Arai, Y; Hiraoka, N; Kanai, Y; Miyagawa, S; Ojima, H; Rokutan, H; Shibata, T; Shimada, K; Shirota, T | 1 |
| Chen, W; Chu, H; Hou, Z; Huang, Q; Li, Q; Man, M; Wang, J; Wang, W; Zhan, M | 1 |
| Dai, J; Dong, Y; Shi, Y; Wang, H; Wang, J; Zhang, Y | 1 |
| Chang, PM; Chao, SC; Chao, Y; Chen, MH; Chen, TW; Huang, CY; Kao, YW; Lin, KJ; Liu, CY; Tzeng, CH; Yang, WL; Yeh, CN | 1 |
5 other study(ies) available for isoxazoles and Cholangiocellular Carcinoma
| Article | Year |
|---|---|
Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Blotting, Western; Cell Proliferation; Cholangiocarcinoma; Female; Flow Cytometry; Follow-Up Studies; HSP90 Heat-Shock Proteins; Humans; Imidazoles; Immunoenzyme Techniques; Isoxazoles; Male; Membrane Potential, Mitochondrial; Middle Aged; Oxidative Stress; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinolines; Rats; Rats, Sprague-Dawley; Resorcinols; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Heat Shock Protein 90 Is a Potential Therapeutic Target in Cholangiocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Cell Line, Tumor; Cholangiocarcinoma; Disease Models, Animal; Female; Follow-Up Studies; HSP90 Heat-Shock Proteins; Humans; Immunohistochemistry; Isoxazoles; Male; Mice; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Prognosis; Resorcinols; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
FXR agonists enhance the sensitivity of biliary tract cancer cells to cisplatin via SHP dependent inhibition of Bcl-xL expression.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; bcl-X Protein; Biliary Tract; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chenodeoxycholic Acid; Cholangiocarcinoma; Cisplatin; Down-Regulation; Drug Synergism; Frataxin; Gallbladder Neoplasms; Humans; Iron-Binding Proteins; Isoxazoles; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 6; STAT3 Transcription Factor | 2016 |
Impact of bile acids on the growth of human cholangiocarcinoma via FXR.
Topics: Animals; Bile Acids and Salts; Cell Line; Cholangiocarcinoma; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Isoxazoles; Mice; Mice, Nude; Neoplasms, Experimental; Receptors, Cytoplasmic and Nuclear | 2011 |
Gene expression-based chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzoquinones; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cell Survival; Cholangiocarcinoma; Drug Evaluation, Preclinical; Female; G2 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Genomics; HSP90 Heat-Shock Proteins; Humans; Inhibitory Concentration 50; Isoxazoles; Lactams, Macrocyclic; Liver Neoplasms, Experimental; Male; MAP Kinase Signaling System; Middle Aged; Oligonucleotide Array Sequence Analysis; Rats; Rats, Sprague-Dawley; Resorcinols; Transcriptome; Tumor Burden | 2013 |